Streetbeat News

Price Targets

APLS

Stifel analyst Annabel Samimy has maintained a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raised the price target from $60 to $65.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:52 pm

IMO

CIBC analyst Dennis Fong maintains a Neutral rating on Imperial Oil (AMEX:IMO) and raises the price target from $75 to $76.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:48 pm

CNQ

CIBC analyst Dennis Fong has maintained an 'Outperformer' rating on Canadian Natural Res (NYSE:CNQ) and raised the price target from C$90 to C$93.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:46 pm

CCO

Citigroup analyst Jason Bazinet has maintained a Neutral rating on Clear Channel Outdoor (NYSE:CCO) and lowered the price target from $1.5 to $1.4.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:39 pm

EIGR

Citigroup analyst Yigal Nochomovitz maintains a 'Buy' rating on Eiger BioPharmaceuticals but lowers the price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:37 pm

GRCL

Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Gracell Biotechnologies (NASDAQ:GRCL), but lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:35 pm

GRTX

Citigroup analyst Yigal Nochomovitz has maintained a Neutral rating on Galera Therapeutics (NASDAQ:GRTX) and lowered the price target from $0.4 to $0.25.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:34 pm

O

Citigroup analyst Michael Bilerman maintains a Neutral rating on Realty Income (NYSE:O) and lowers the price target from $65 to $61.5.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:32 pm

QTWO

Citigroup analyst Andrew Schmidt has maintained a 'Buy' rating on Q2 Holdings (NYSE:QTWO) and raised the price target from $31 to $39.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2023 | 4:31 pm

VERV

Cantor Fitzgerald analyst Rick Bienkowski has reiterated a Neutral rating on Verve Therapeutics (NASDAQ:VERV) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

August 29, 2023 | 4:04 pm